Journal of Ocular Pharmacology and Therapeutics

Journal of Ocular Pharmacology and Therapeutics is the only peer-reviewed journal that combines the fields of ophthalmology and pharmacology to enable optimal treatment and prevention of ocular diseases and disorders. The Journal's 2020 impact factor is 2.671* and the 2021 average time to decision for original articles is 20.17 days. The Journal also has an increase in full-text article download year-to-date. These achievements uphold the Journal’s position as a leading peer-reviewed journal.

Journal of Ocular Pharmacology and Therapeutics welcomes original research, editorials, review articles, and commentaries. Full length manuscripts should be approximately 3,000 – 4,500 words in length with a 250-word maximum for abstracts.

Suggested topic areas include, among others:

• Drug discovery and development
• Mechanisms of drug action
• Drug delivery, nanomedicine, and nanotechnology
• Biopharmaceutics, pharmacokinetics, pharmacodynamics, and mathematical modeling
• Drug transporters and drug metabolism
• Pre-clinical and early-stage clinical trial results
• Gene and cell-based therapies
• Combination products
• Ocular pharmacotherapy/clinical trials/biomarkers
• Ocular toxicology and toxicokinetics
• Dry eye and ocular surface diseases
• Corneal diseases
• Glaucoma and optic neuropathies
• Retinal diseases
• Lens and cataract
• Ocular infection and trauma
• Ocular inflammatory and immune disorders
• Ocular ischemia and blood flow
• Ocular metabolic disorders
• Ocular pain
• Oculomotor complications
• Proliferative disorders of the eye
• Therapeutics for myopia and refractive errors
• Therapeutics for strabismus, ambylopia, and visual processing

Advantages of publishing in Journal of Ocular Pharmacology and Therapeutics include:

• Fast and user-friendly electronic submission
• Rapid, high-quality peer review
• Immediate deposit to PubMed and other indexing services upon online publication
• Maximum exposure: accessible in 170 countries worldwide
• Comprehensive suite of specialized editorial services available
• Open Access options available

Journal of Ocular Pharmacology and Therapeutics is under the editorial leadership of Uday B. Kompella, PhD, University of Colorado Anschutz Medical Campus; and his Associate Editors: Linda D. Hazlett, PhD, Wayne State University School of Medicine, Ocular Surface Pharmacology; Michael Niesman, PhD, MingSight Pharmaceuticals, Retinal Pharmacology; Naj A. Sharif, PhD, FARVO, Santen Incorporated, Pre-clinical Ocular Pharmacology; Carol B. Toris, PhD, University of Nebraska Medical Center, Aqueous Humor Dynamics; and an editorial board of leading experts. View the entire editorial board.

Visit the Journal's website to learn more, read past issues, and view author submission guidelines.

*2020 Journal Citation Reports (Clarivate, 2021)